Bio-Path Holdings, Inc. (BPTH) Stock

Bio-Path Holdings, Inc., headquartered in Bellaire, Texas, is a pioneering clinical and preclinical stage biopharmaceutical company focused on advancing RNAi nanoparticle drug development in oncology. Founded in 2007, the company specializes in leveraging its proprietary DNAbilize technology, which incorporates P-ethoxy, a DNA backbone modification designed to enhance drug delivery and protect therapeutic DNA from degradation.

At the forefront of its innovative pipeline is prexigebersen, Bio-Path's lead drug candidate currently undergoing Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, the company is developing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia, and Liposomal STAT3 in preclinical stages targeting pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings also pursues prexigebersen-A for various solid tumors, underscoring its commitment to addressing diverse oncological challenges.

Bio-Path Holdings continues to innovate in the field of RNAi nanoparticle drug delivery, aiming to transform cancer treatment paradigms through its robust research and development efforts. With a strategic focus on expanding its therapeutic portfolio and advancing clinical programs, the company is dedicated to improving outcomes for patients worldwide facing complex malignancies.